Johnson & Johnson today took the wraps off its latest collection of collaborations aimed at everything from setting up new "asset-centric" drug development operations with a partner in China to exploring ways to prevent Type 1 diabetes with investigators at Washington University. Its latest tally of 17 new deals and developments also includes a new Innovation hub in Sweden and brings its global total for its deal teams to more than 200 projects over two years running.
The infants and young children who suffer from rare cases of spinal muscular atrophy, or SMA, don't live long. But Isis Pharmaceuticals says that the latest update on the infants enrolled in their mid-stage program for ISIS-SMNrx shows that toddlers with the most severe form of the disease have been getting progressively stronger and living longer while taking this drug.
INC Research has started what it says is the industry's first site advocacy group, gathering study investigators to discuss how to improve speed and results in R&D.
Researchers have developed a soft, conductive electronic polymer mesh that can be injected into the brain to monitor and stimulate it at the level of individual neurons. They have published preclinical data on the device in the latest issue of Nature Nanotechnology.
Germany's Biotronik touted a recent study of its CE-marked Pulsar-18 stent for peripheral artery disease, saying the data showed the device can be used in challenging cases of the condition.
Novartis has the first next-gen psoriasis med on the market in Cosentyx, and it's been spending money to take that first-to-market advantage as far as it can. But the Swiss drugmaker wants the treatment to be first in other indications, too. On that front, it got a boost on Wednesday with some new results in ankylosing spondylitis.
Getting innovative medical devices that fill a critical patient need to the U.S. market faster is a stated goal of the Food and Drug Administration. To that end, it recently finalized its Expedited Access Pathway (EAP) in an April guidance. Cohera Medical is among the first to tread this path; it has received an EAP designation and priority processing status for its Sylys resorbable synthetic sealant for use in gastrointestinal surgical procedures to prevent leakage.
Biogen's recent early-stage success in Alzheimer's disease has galvanized R&D in the field, and Roche, owner of a similar treatment, is considering whether to tee off another Phase III trial for its once-failed antibody.
Researchers from MIT demonstrated that a 3-mm-long microdevice holding up to 16 different drugs and drug combinations can release those drugs when implanted directly in a tumor to then determine the tumor's sensitivity to those therapies.
Braeburn Pharmaceuticals is confident about FDA approval of its Probuphine subdermal implant to treat opioid addiction after its pivotal trial demonstrated it worked at least as well as sublingually administered buprenorphine/naloxone. But an unexpected rejection of the candidate by the FDA in 2013 means the outcome is far from certain.